Literature DB >> 8491757

Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treated.

M Markman.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8491757     DOI： 10.1007/BF01218418

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  5 in total

1.  High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.

Authors:  E J Shpall; D Clarke-Pearson; J T Soper; A Berchuck; R B Jones; R C Bast; M Ross; Y Lidor; K Vanacek; T Tyler
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

2.  Paying for patient care in treatment research--who is responsible?

Authors:  R E Wittes
Journal:  Cancer Treat Rep       Date:  1987-02

3.  The crisis in clinical cancer research. Third-party insurance and investigational therapy.

Authors:  K Antman; L E Schnipper; E Frei
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

4.  Design of phase I and II clinical trials in cancer: a statistician's view.

Authors:  N L Geller
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

5.  Reimbursement policies constrain the practice of oncology.

Authors:  T Laetz; G Silberman
Journal:  JAMA       Date:  1991-12-04       Impact factor: 56.272
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.